Global Cord Blood Corporation (NYSE: CO) Stock Competitors & Peer Comparison
See CO's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CO and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CO | $2.99 | +34.58% | 400.1M | 5.06 | $0.59 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.67% |
| TMO | $680.27 | +0.55% | 249.2B | 29.10 | $23.16 | +0.27% |
| DHR | $232.55 | +1.22% | 162B | 28.88 | $7.98 | +0.67% |
| NTRA | $406.02 | +1.16% | 58.2B | -306.02 | -$1.32 | N/A |
| A | $175.79 | +1.09% | 48.8B | 29.78 | $5.81 | +0.59% |
| IQV | $280.02 | +0.61% | 46B | 23.03 | $12.13 | N/A |
| WAT | $459.11 | +0.77% | 44.5B | 33.16 | $13.68 | N/A |
| IDXX | $569.78 | +0.53% | 44.1B | 39.41 | $14.22 | N/A |
| ILMN | $272.35 | +1.09% | 40.7B | 53.56 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
CO vs DHR-PB Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CO's ROE is +0.11%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, CO is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for CO.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
CO vs TMO Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, TMO has a market cap of 249.2B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while TMO trades at $680.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas TMO's P/E ratio is 29.10. In terms of profitability, CO's ROE is +0.11%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CO is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for CO.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
CO vs DHR Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DHR has a market cap of 162B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while DHR trades at $232.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DHR's P/E ratio is 28.88. In terms of profitability, CO's ROE is +0.11%, compared to DHR's ROE of +0.08%. Regarding short-term risk, CO is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for CO.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
CO vs NTRA Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NTRA has a market cap of 58.2B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while NTRA trades at $406.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NTRA's P/E ratio is -306.02. In terms of profitability, CO's ROE is +0.11%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, CO is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for CO.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
CO vs A Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, A has a market cap of 48.8B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while A trades at $175.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas A's P/E ratio is 29.78. In terms of profitability, CO's ROE is +0.11%, compared to A's ROE of +0.20%. Regarding short-term risk, CO is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for CO.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
CO vs IQV Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, IQV has a market cap of 46B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while IQV trades at $280.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas IQV's P/E ratio is 23.03. In terms of profitability, CO's ROE is +0.11%, compared to IQV's ROE of +0.22%. Regarding short-term risk, CO is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for CO.Check IQV's competition here
Waters Corporation (NYSE: WAT)
CO vs WAT Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, WAT has a market cap of 44.5B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while WAT trades at $459.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas WAT's P/E ratio is 33.16. In terms of profitability, CO's ROE is +0.11%, compared to WAT's ROE of +0.02%. Regarding short-term risk, CO is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for CO.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
CO vs IDXX Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, IDXX has a market cap of 44.1B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while IDXX trades at $569.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas IDXX's P/E ratio is 39.41. In terms of profitability, CO's ROE is +0.11%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, CO is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for CO.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
CO vs ILMN Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ILMN has a market cap of 40.7B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while ILMN trades at $272.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ILMN's P/E ratio is 53.56. In terms of profitability, CO's ROE is +0.11%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, CO is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for CO.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
CO vs MTD Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MTD has a market cap of 33.4B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while MTD trades at $1,672.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MTD's P/E ratio is 38.35. In terms of profitability, CO's ROE is +0.11%, compared to MTD's ROE of -12.00%. Regarding short-term risk, CO is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for CO.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
CO vs DGX Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DGX has a market cap of 26.7B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while DGX trades at $243.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DGX's P/E ratio is 23.85. In terms of profitability, CO's ROE is +0.11%, compared to DGX's ROE of +0.15%. Regarding short-term risk, CO is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for CO.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
CO vs LH Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, LH has a market cap of 26.7B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while LH trades at $329.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas LH's P/E ratio is 19.53. In terms of profitability, CO's ROE is +0.11%, compared to LH's ROE of +0.12%. Regarding short-term risk, CO is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for CO.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
CO vs GH Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GH has a market cap of 22.7B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while GH trades at $173.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GH's P/E ratio is -48.45. In terms of profitability, CO's ROE is +0.11%, compared to GH's ROE of +2.11%. Regarding short-term risk, CO is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for CO.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
CO vs EXAS Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas EXAS's P/E ratio is -95.37. In terms of profitability, CO's ROE is +0.11%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, CO is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for CO.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
CO vs MEDP Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MEDP has a market cap of 18.7B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while MEDP trades at $677.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MEDP's P/E ratio is 39.23. In terms of profitability, CO's ROE is +0.11%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, CO is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for CO.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
CO vs RVTY Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, RVTY has a market cap of 17.7B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while RVTY trades at $161.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas RVTY's P/E ratio is 29.67. In terms of profitability, CO's ROE is +0.11%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, CO is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for CO.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
CO vs ILMNV Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ILMNV's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.11%, compared to ILMNV's ROE of N/A. Regarding short-term risk, CO is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for CO.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
CO vs CRL Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CRL has a market cap of 16.6B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while CRL trades at $357.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CRL's P/E ratio is 34.87. In terms of profitability, CO's ROE is +0.11%, compared to CRL's ROE of -0.08%. Regarding short-term risk, CO is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for CO.Check CRL's competition here
PerkinElmer, Inc. (NYSE: PKI)
CO vs PKI Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PKI's P/E ratio is 41.45. In terms of profitability, CO's ROE is +0.11%, compared to PKI's ROE of +0.03%. Regarding short-term risk, CO is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for CO.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
CO vs ICLR Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ICLR has a market cap of 14.3B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while ICLR trades at $184.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ICLR's P/E ratio is 15.11. In terms of profitability, CO's ROE is +0.11%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, CO is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for CO.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
CO vs QGEN Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while QGEN trades at $50.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas QGEN's P/E ratio is 20.82. In terms of profitability, CO's ROE is +0.11%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, CO is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for CO.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
CO vs GRAL Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while GRAL trades at $141.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GRAL's P/E ratio is -13.59. In terms of profitability, CO's ROE is +0.11%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, CO is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for CO.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
CO vs RDNT Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while RDNT trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas RDNT's P/E ratio is 152.91. In terms of profitability, CO's ROE is +0.11%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, CO is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for CO.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
CO vs SHC Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while SHC trades at $18.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas SHC's P/E ratio is 18.85. In terms of profitability, CO's ROE is +0.11%, compared to SHC's ROE of +0.27%. Regarding short-term risk, CO is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for CO.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
CO vs BLLN Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BLLN has a market cap of 5.1B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while BLLN trades at $110.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BLLN's P/E ratio is 153.96. In terms of profitability, CO's ROE is +0.11%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, CO is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for CO.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
CO vs SYNH Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CO's ROE is +0.11%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CO is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for CO.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
CO vs VCYT Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while VCYT trades at $48.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas VCYT's P/E ratio is 23.97. In terms of profitability, CO's ROE is +0.11%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, CO is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for CO.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
CO vs CDNA Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CDNA has a market cap of 3.6B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while CDNA trades at $69.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CDNA's P/E ratio is 82.39. In terms of profitability, CO's ROE is +0.11%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, CO is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for CO.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
CO vs OLK Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas OLK's P/E ratio is -96.59. In terms of profitability, CO's ROE is +0.11%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CO is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for CO.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
CO vs NEO Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while NEO trades at $16.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NEO's P/E ratio is 127.62. In terms of profitability, CO's ROE is +0.11%, compared to NEO's ROE of -0.06%. Regarding short-term risk, CO is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for CO.Check NEO's competition here
Personalis, Inc. (NASDAQ: PSNL)
CO vs PSNL Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while PSNL trades at $15.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PSNL's P/E ratio is -14.52. In terms of profitability, CO's ROE is +0.11%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, CO is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for CO.Check PSNL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
CO vs WGS Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, WGS has a market cap of 1.7B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while WGS trades at $62.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas WGS's P/E ratio is 155.97. In terms of profitability, CO's ROE is +0.11%, compared to WGS's ROE of -0.39%. Regarding short-term risk, CO is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for CO.Check WGS's competition here
OPKO Health, Inc. (NASDAQ: OPK)
CO vs OPK Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while OPK trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas OPK's P/E ratio is -18.33. In terms of profitability, CO's ROE is +0.11%, compared to OPK's ROE of -0.06%. Regarding short-term risk, CO is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for CO.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
CO vs CSTL Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while CSTL trades at $33.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CSTL's P/E ratio is -50.12. In terms of profitability, CO's ROE is +0.11%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, CO is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for CO.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
CO vs GRALV Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GRALV's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.11%, compared to GRALV's ROE of N/A. Regarding short-term risk, CO is more volatile compared to GRALV. This indicates higher risk in terms of short-term price fluctuations for CO.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
CO vs MYGN Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MYGN has a market cap of 557.6M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while MYGN trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MYGN's P/E ratio is -44.85. In terms of profitability, CO's ROE is +0.11%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, CO is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for CO.Check MYGN's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
CO vs FLGT Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, FLGT has a market cap of 553.1M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while FLGT trades at $20.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas FLGT's P/E ratio is 2010.00. In terms of profitability, CO's ROE is +0.11%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, CO is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for CO.Check FLGT's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
CO vs FLDM Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CO's ROE is +0.11%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, CO is more volatile compared to FLDM. This indicates higher risk in terms of short-term price fluctuations for CO.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
CO vs XGN Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, XGN has a market cap of 176.1M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while XGN trades at $7.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas XGN's P/E ratio is -8.98. In terms of profitability, CO's ROE is +0.11%, compared to XGN's ROE of -1.22%. Regarding short-term risk, CO is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for CO.Check XGN's competition here
Biodesix, Inc. (NASDAQ: BDSX)
CO vs BDSX Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BDSX has a market cap of 172.4M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while BDSX trades at $21.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BDSX's P/E ratio is -6.68. In terms of profitability, CO's ROE is +0.11%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, CO is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for CO.Check BDSX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
CO vs GTH Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GTH's P/E ratio is -1.11. In terms of profitability, CO's ROE is +0.11%, compared to GTH's ROE of -1.01%. Regarding short-term risk, CO is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for CO.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
CO vs GENE Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GENE's P/E ratio is -38.25. In terms of profitability, CO's ROE is +0.11%, compared to GENE's ROE of -1.85%. Regarding short-term risk, CO is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for CO.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
CO vs FRNM Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, FRNM has a market cap of 104.2M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while FRNM trades at $12.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas FRNM's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.11%, compared to FRNM's ROE of N/A. Regarding short-term risk, CO is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for CO.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
CO vs IMDX Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, IMDX has a market cap of 92.6M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while IMDX trades at $2.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas IMDX's P/E ratio is -1.90. In terms of profitability, CO's ROE is +0.11%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, CO is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for CO.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
CO vs PRPO Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PRPO has a market cap of 37.1M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while PRPO trades at $19.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PRPO's P/E ratio is -31.92. In terms of profitability, CO's ROE is +0.11%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, CO is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for CO.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
CO vs AKU Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas AKU's P/E ratio is -0.13. In terms of profitability, CO's ROE is +0.11%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CO is more volatile compared to AKU. This indicates higher risk in terms of short-term price fluctuations for CO.Check AKU's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
CO vs QUCY Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, QUCY has a market cap of 23M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while QUCY trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas QUCY's P/E ratio is -0.05. In terms of profitability, CO's ROE is +0.11%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, CO is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for CO.Check QUCY's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
CO vs BIAF Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BIAF has a market cap of 17.6M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while BIAF trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BIAF's P/E ratio is -0.33. In terms of profitability, CO's ROE is +0.11%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, CO is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for CO.Check BIAF's competition here
MDxHealth S.A. (NASDAQ: MDXH)
CO vs MDXH Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MDXH has a market cap of 17.5M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while MDXH trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MDXH's P/E ratio is -0.25. In terms of profitability, CO's ROE is +0.11%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, CO is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for CO.Check MDXH's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
CO vs CEMI Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CEMI's P/E ratio is -0.63. In terms of profitability, CO's ROE is +0.11%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, CO is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for CO.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
CO vs ENZ Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ENZ's P/E ratio is -2.24. In terms of profitability, CO's ROE is +0.11%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, CO is more volatile compared to ENZ. This indicates higher risk in terms of short-term price fluctuations for CO.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
CO vs PMD Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PMD's P/E ratio is -5.24. In terms of profitability, CO's ROE is +0.11%, compared to PMD's ROE of -0.32%. Regarding short-term risk, CO is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for CO.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
CO vs ME Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ME's P/E ratio is -0.03. In terms of profitability, CO's ROE is +0.11%, compared to ME's ROE of -3.47%. Regarding short-term risk, CO is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for CO.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
CO vs MYNZ Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, CO's ROE is +0.11%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, CO is more volatile compared to MYNZ. This indicates higher risk in terms of short-term price fluctuations for CO.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
CO vs BNR Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BNR has a market cap of 12.5M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while BNR trades at $12.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BNR's P/E ratio is -13.59. In terms of profitability, CO's ROE is +0.11%, compared to BNR's ROE of -0.13%. Regarding short-term risk, CO is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for CO.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
CO vs CHEK Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CHEK's P/E ratio is -0.43. In terms of profitability, CO's ROE is +0.11%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, CO is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for CO.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
CO vs CNTG Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CO's ROE is +0.11%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CO is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for CO.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
CO vs APDN Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas APDN's P/E ratio is -0.10. In terms of profitability, CO's ROE is +0.11%, compared to APDN's ROE of -7.23%. Regarding short-term risk, CO is more volatile compared to APDN. This indicates higher risk in terms of short-term price fluctuations for CO.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
CO vs NDRA Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while NDRA trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NDRA's P/E ratio is -0.70. In terms of profitability, CO's ROE is +0.11%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, CO is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for CO.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
CO vs BIAFW Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BIAFW has a market cap of 5.7M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BIAFW's P/E ratio is 0.61. In terms of profitability, CO's ROE is +0.11%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, CO is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for CO.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
CO vs NVTA Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CO's ROE is +0.11%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, CO is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for CO.Check NVTA's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
CO vs ADVB Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ADVB has a market cap of 5.2M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while ADVB trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ADVB's P/E ratio is -28.82. In terms of profitability, CO's ROE is +0.11%, compared to ADVB's ROE of -0.20%. Regarding short-term risk, CO is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for CO.Check ADVB's competition here
LumiraDx Limited (NASDAQ: LMDXW)
CO vs LMDXW Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CO's ROE is +0.11%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CO is more volatile compared to LMDXW. This indicates higher risk in terms of short-term price fluctuations for CO.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
CO vs LMDX Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CO's ROE is +0.11%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CO is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for CO.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
CO vs DMTK Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CO's ROE is +0.11%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, CO is more volatile compared to DMTK. This indicates higher risk in terms of short-term price fluctuations for CO.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
CO vs NOTV Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NOTV's P/E ratio is -0.03. In terms of profitability, CO's ROE is +0.11%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, CO is more volatile compared to NOTV. This indicates higher risk in terms of short-term price fluctuations for CO.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
CO vs SQL Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas SQL's P/E ratio is -0.40. In terms of profitability, CO's ROE is +0.11%, compared to SQL's ROE of -30.46%. Regarding short-term risk, CO is more volatile compared to SQL. This indicates higher risk in terms of short-term price fluctuations for CO.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
CO vs AWH Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas AWH's P/E ratio is -0.09. In terms of profitability, CO's ROE is +0.11%, compared to AWH's ROE of +1.62%. Regarding short-term risk, CO is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for CO.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
CO vs ISPC Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ISPC has a market cap of 2.1M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while ISPC trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ISPC's P/E ratio is -0.03. In terms of profitability, CO's ROE is +0.11%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, CO is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for CO.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
CO vs HTGM Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CO's ROE is +0.11%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CO is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for CO.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
CO vs BIOC Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CO's ROE is +0.11%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CO is more volatile compared to BIOC. This indicates higher risk in terms of short-term price fluctuations for CO.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
CO vs SQLLW Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, CO's ROE is +0.11%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, CO is more volatile compared to SQLLW. This indicates higher risk in terms of short-term price fluctuations for CO.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
CO vs WGSWW Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, CO's ROE is +0.11%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, CO is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for CO.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
CO vs OCDX Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CO's ROE is +0.11%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CO is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for CO.Check OCDX's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
CO vs CHEKZ Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.11%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, CO is more volatile compared to CHEKZ. This indicates higher risk in terms of short-term price fluctuations for CO.Check CHEKZ's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
CO vs BNGOW Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BNGOW's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.11%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, CO is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for CO.Check BNGOW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
CO vs MEUSW Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.11%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, CO is more volatile compared to MEUSW. This indicates higher risk in terms of short-term price fluctuations for CO.Check MEUSW's competition here
Danaher Corporation (NYSE: DHR-PA)
CO vs DHR-PA Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CO's ROE is +0.11%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, CO is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for CO.Check DHR-PA's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
CO vs NDRAW Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NDRAW's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.11%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, CO is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for CO.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
CO vs PRXL Comparison October 2026
Global Cord Blood Corporation (NYSE: CO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, CO is priced at $2.99 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PRXL's P/E ratio is 42.97. In terms of profitability, CO's ROE is +0.11%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, CO is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for CO.Check PRXL's competition here